Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 5/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10106454 | 0.90 | DHODH (0.33) | GRM4BACE1BACE2DHODHEGFR | |
| SCHEMBL10106233 | 0.73 | EGFR (0.39) | KDRFGFR1FLT1EPHB2FLT4 | |
| SCHEMBL10105801 | 0.71 | MKNK2 (0.39) | KDRFGFR1FLT1EPHB2FLT4 | |
| SCHEMBL10116431 | 0.70 | KDR (0.37) | KDRFGFR1FLT1EPHB2FLT4 | |
| SCHEMBL997705 | 0.70 | RAPGEF4 (0.34) | LRRK2 | |
| SCHEMBL29952346 | 0.70 | RAPGEF4 (0.34) | LRRK2 | |
| SCHEMBL10105808 | 0.69 | GPR119 (0.41) | KDRFGFR1FLT1EPHB2FLT4 | |
| SCHEMBL10120542 | 0.69 | GPR119 (0.42) | BACE2LRRK2 | |
| SCHEMBL10105823 | 0.67 | SRC (0.34) | — | |
| SCHEMBL10116306 | 0.67 | KDR (0.36) | KDRFGFR1FLT1EPHB2FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | GRM4 424/4885BACE1 996/4885BACE2 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.